Semaglutide Does Not Treat Alzheimer’s. Could it Prevent Dementia?
Topline results presented at CTAD revealed that semaglutide definitively failed to benefit people with early symptomatic AD.
NEWS
Cognition Bump from Better Lifestyle: Due to Healthy Heart, Sound Sleep?
CTAD 2025 featured early data on U.S. POINTER’s imaging, neurovascular, and sleep studies.
Latest From GNPC: APOE4 Ages Astrocytes, Cripples Energy Metabolism
Proteomic analyses of thousands of blood samples found that APOE4’s effects start early in life. APOE4 also tied faster astrocyte aging to Alzheimer’s risk.
Brand-New Biomarker for Alzheimer’s: Circulating, Circular RNA
At CTAD, researchers reported that certain circular RNAs in the blood might signal impending onset of Alzheimer’s.
In Early Trial, Vaccine Spurs Glut of Antibodies Against Aβ Aggregates
The AV-1595R vaccine provoked powerful antibody responses in all 12 recipients. A Phase 2 trial is in the works.
You, Too, BCG? Tuberculosis Jab Said to Ward Off Alzheimer’s
At CTAD, data from a Bacillus Calmette-Guerin vaccine trial in diabetes suggest a reshaping of the brain’s protein landscape in ways that might keep AD at bay.
At CTAD: More Hints That Shingles Shot Staves Off Dementia
Add Ontario to the places in which the herpes zoster vaccine has been shown to protect against dementia. Does it also shield against MCI and death?
Trouble with Fujirebio’s FDA-Cleared Blood Test? Or a Lousy Lot?
At CTAD in San Diego, scientists report that false positives ran as high as 40 percent.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- Total Items: 168
-
Jobs
- Total Items: 2
-
Conference Calendar
- Total Items: 64
- Member Directory
Latest Comments